Loading...

Lee Jay Helman

Title(s)Professor of Pediatrics and Medicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Solid Tumors
    NIH/NCI Z01SC006891
    Role: Principal Investigator
    Molecular Biology of Pediatric Tumors
    NIH/NCI Z01SC006892
    Role: Principal Investigator
    Tumor and Metastasis Biology
    NIH/NCI ZIABC010566
    Role: Principal Investigator
    Clinical Studies in Pediatric Solid Tumors
    NIH/NCI ZIASC006891
    Role: Principal Investigator
    Molecular Biology of Pediatric Tumors
    NIH/NCI ZIASC006892
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Yohe ME, Heske CM, Stewart E, Adamson PC, Ahmed N, Antonescu CR, Chen E, Collins N, Ehrlich A, Galindo RL, Gryder BE, Hahn H, Hammond S, Hatley ME, Hawkins DS, Hayes MN, Hayes-Jordan A, Helman LJ, Hettmer S, Ignatius MS, Keller C, Khan J, Kirsch DG, Linardic CM, Lupo PJ, Rota R, Shern JF, Shipley J, Sindiri S, Tapscott SJ, Vakoc CR, Wexler LH, Langenau DM. Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatr Blood Cancer. 2019 Jun 21; e27869. PMID: 31222885.
      View in: PubMed
    2. Issaq SH, Mendoza A, Fox SD, Helman LJ. Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growth. Oncogenesis. 2019 Feb 26; 8(3):20. PMID: 30808861.
      View in: PubMed
    3. Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, Bartels CF, Kapteijn MY, Hung S, Mendoza A, Dhillon G, Chee DR, Myers JT, Allen F, Gambarotti M, Righi A, DiFeo A, Rubin BP, Huang AY, Meltzer PS, Helman LJ, Picci P, Versteeg HH, Stamatoyannopoulos JA, Khanna C, Scacheri PC. Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med. 2018 Apr 10; 24(4):525. PMID: 29634688.
      View in: PubMed
    4. Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, Bartels CF, Kapteijn MY, Hung S, Mendoza A, Dhillon G, Chee DR, Myers JT, Allen F, Gambarotti M, Righi A, DiFeo A, Rubin BP, Huang AY, Meltzer PS, Helman LJ, Picci P, Versteeg HH, Stamatoyannopoulos JA, Khanna C, Scacheri PC. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med. 2018 Feb; 24(2):176-185. PMID: 29334376.
      View in: PubMed
    5. Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BC. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017; 2017:8685638. PMID: 29138631.
      View in: PubMed
    6. Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 01; 23(23):7301-7311. PMID: 28899971.
      View in: PubMed
    7. Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol. 2017 Sep; 80(3):645-652. PMID: 28735378.
      View in: PubMed
    8. Kalish JM, Doros L, Helman LJ, Hennekam RC, Kuiper RP, Maas SM, Maher ER, Nichols KE, Plon SE, Porter CC, Rednam S, Schultz KAP, States LJ, Tomlinson GE, Zelley K, Druley TE. Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. Clin Cancer Res. 2017 07 01; 23(13):e115-e122. PMID: 28674120.
      View in: PubMed
    9. Kummar S, O'Sullivan Coyne G, Do KT, Turkbey B, Meltzer PS, Polley E, Choyke PL, Meehan R, Vilimas R, Horneffer Y, Juwara L, Lih A, Choudhary A, Mitchell SA, Helman LJ, Doroshow JH, Chen AP. Clinical Activity of the ?-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). J Clin Oncol. 2017 May 10; 35(14):1561-1569. PMID: 28350521.
      View in: PubMed
    10. Weldon CB, Madenci AL, Boikos SA, Janeway KA, George S, von Mehren M, Pappo AS, Schiffman JD, Wright J, Trent JC, Pacak K, Stratakis CA, Helman LJ, La Quaglia MP. Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol. 2017 Feb 10; 35(5):523-528. PMID: 28029307.
      View in: PubMed
    11. Heske CM, Yeung C, Mendoza A, Baumgart JT, Edessa LD, Wan X, Helman LJ. The Role of PDGFR-ß Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma. Transl Oncol. 2016 Dec; 9(6):540-547. PMID: 27835791.
      View in: PubMed
    12. Lizardo MM, Morrow JJ, Miller TE, Hong ES, Ren L, Mendoza A, Halsey CH, Scacheri PC, Helman LJ, Khanna C. Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression. Neoplasia. 2016 Oct 28; 18(11):699-710. PMID: 27973325.
      View in: PubMed
    13. Ferraz Nogueira Filho MA, Peer CJ, Nguyen J, McCalla A, Helman L, Figg WD. A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. J Pharm Biomed Anal. 2017 Jan 05; 132:223-226. PMID: 27768921.
      View in: PubMed
    14. Heske CM, Mendoza A, Edessa LD, Baumgart JT, Lee S, Trepel J, Proia DA, Neckers L, Helman LJ. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma. Oncotarget. 2016 Oct 04; 7(40):65540-65552. PMID: 27608846.
      View in: PubMed
    15. Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, Trent JC, von Mehren M, Wright JA, Schiffman JD, Raygada M, Pacak K, Meltzer PS, Miettinen MM, Stratakis C, Janeway KA, Helman LJ. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016 Jul 01; 2(7):922-8. PMID: 27011036.
      View in: PubMed
    16. Khan J, Helman LJ. Precision Therapy for Pediatric Cancers. JAMA Oncol. 2016 May 01; 2(5):575-577. PMID: 26822032.
      View in: PubMed
    17. Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith M, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clin Cancer Res. 2016 Aug 15; 22(16):4105-18. PMID: 26979396.
      View in: PubMed
    18. Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. 2016 Feb 23; 7(8):8613-24. PMID: 26802024.
      View in: PubMed
    19. LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, London C, Mason N, Mazcko C, Olson PN, Page R, Teicher BA, Thamm DH, Trent JM, Vail DM, Khanna C. Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. Sci Transl Med. 2016 Feb 03; 8(324):324ps5. PMID: 26843188.
      View in: PubMed
    20. Hyun O J, Luber BS, Leal JP, Wang H, Bolejack V, Schuetze SM, Schwartz LH, Helman LJ, Reinke D, Baker LH, Wahl RL. Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor. J Nucl Med. 2016 May; 57(5):735-40. PMID: 26795289.
      View in: PubMed
    21. Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, Helman LJ, Martin SE, Caplen NJ. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma. Cell Rep. 2016 Jan 26; 14(3):598-610. PMID: 26776507.
      View in: PubMed
    22. Venkatramani R, Murray J, Helman L, Meyer W, Hicks MJ, Krance R, Lau C, Jo E, Chintagumpala M. Risk-Based Therapy for Localized Osteosarcoma. Pediatr Blood Cancer. 2016 Mar; 63(3):412-7. PMID: 26501936.
      View in: PubMed
    23. Baselga J, Bhardwaj N, Cantley LC, DeMatteo R, DuBois RN, Foti M, Gapstur SM, Hahn WC, Helman LJ, Jensen RA, Paskett ED, Lawrence TS, Lutzker SG, Szabo E. AACR Cancer Progress Report 2015. Clin Cancer Res. 2015 Oct 01; 21(19 Suppl):S1-128. PMID: 26429991.
      View in: PubMed
    24. Pappo AS, Furman WL, Schultz KA, Ferrari A, Helman L, Krailo MD. Rare Tumors in Children: Progress Through Collaboration. J Clin Oncol. 2015 Sep 20; 33(27):3047-54. PMID: 26304909.
      View in: PubMed
    25. Boikos SA, Xekouki P, Fumagalli E, Faucz FR, Raygada M, Szarek E, Ball E, Kim SY, Miettinen M, Helman LJ, Carney JA, Pacak K, Stratakis CA. Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. Eur J Hum Genet. 2016 Apr; 24(4):569-73. PMID: 26173966.
      View in: PubMed
    26. Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, de Toledo SR, Petrilli AS, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF, Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ, Savage SA. A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discov. 2015 Sep; 5(9):920-31. PMID: 26084801.
      View in: PubMed
    27. Wan X, Yeung C, Heske C, Mendoza A, Helman LJ. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma. Neoplasia. 2015 Apr; 17(4):358-66. PMID: 25925378.
      View in: PubMed
    28. Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, Meltzer PS, Pommier Y. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clin Cancer Res. 2015 Sep 15; 21(18):4184-93. PMID: 25779942.
      View in: PubMed
    29. Thiele CJ, Helman LJ. Preface: The Status of Pediatric Solid Tumors in 2015. Crit Rev Oncog. 2015; 20(3-4):v-vi. PMID: 26591907.
      View in: PubMed
    30. Killian JK, Miettinen M, Walker RL, Wang Y, Zhu YJ, Waterfall JJ, Noyes N, Retnakumar P, Yang Z, Smith WI, Killian MS, Lau CC, Pineda M, Walling J, Stevenson H, Smith C, Wang Z, Lasota J, Kim SY, Boikos SA, Helman LJ, Meltzer PS. Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci Transl Med. 2014 Dec 24; 6(268):268ra177. PMID: 25540324.
      View in: PubMed
    31. Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ, Houghton PJ, Khan J, Langenau DM, Linardic CM, Pal R, Partridge TA, Pavlath GK, Rota R, Schäfer BW, Shipley J, Stillman B, Wexler LH, Wagers AJ, Keller C. Rhabdomyosarcoma: current challenges and their implications for developing therapies. Cold Spring Harb Perspect Med. 2014 Nov 03; 4(11):a025650. PMID: 25368019.
      View in: PubMed
    32. Roth J, Peer CJ, Widemann B, Cole DE, Ershler R, Helman L, Schrump D, Figg WD. Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Nov 01; 970:95-101. PMID: 25247492.
      View in: PubMed
    33. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A, Kaaks R, Kamat AM, Kamineni A, Karagas M, Khanna C, Khaw KT, Kim C, Kim IS, Kim JH, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, Lau CC, Lecanda F, Lee KM, Lee MP, Le Marchand L, Lerner SP, Li D, Liao LM, Lim WY, Lin D, Lin J, Lindstrom S, Linet MS, Lissowska J, Liu J, Ljungberg B, Lloreta J, Lu D, Ma J, Malats N, Mannisto S, Marina N, Mastrangelo G, Matsuo K, McGlynn KA, McKean-Cowdin R, McNeill LH, McWilliams RR, Melin BS, Meltzer PS, Mensah JE, Miao X, Michaud DS, Mondul AM, Moore LE, Muir K, Niwa S, Olson SH, Orr N, Panico S, Park JY, Patel AV, Patino-Garcia A, Pavanello S, Peeters PH, Peplonska B, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Pu X, Purdue MP, Qiao YL, Rajaraman P, Riboli E, Risch HA, Rodabough RJ, Rothman N, Ruder AM, Ryu JS, Sanson M, Schned A, Schumacher FR, Schwartz AG, Schwartz KL, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Severi G, Shen H, Shen M, Shete S, Shiraishi K, Shu XO, Siddiq A, Sierrasesumaga L, Sierri S, Loon Sihoe AD, Silverman DT, Simon M, Southey MC, Spector L, Spitz M, Stampfer M, Stattin P, Stern MC, Stevens VL, Stolzenberg-Solomon RZ, Stram DO, Strom SS, Su WC, Sund M, Sung SW, Swerdlow A, Tan W, Tanaka H, Tang W, Tang ZZ, Tardon A, Tay E, Taylor PR, Tettey Y, Thomas DM, Tirabosco R, Tjonneland A, Tobias GS, Toro JR, Travis RC, Trichopoulos D, Troisi R, Truelove A, Tsai YH, Tucker MA, Tumino R, Van Den Berg D, Van Den Eeden SK, Vermeulen R, Vineis P, Visvanathan K, Vogel U, Wang C, Wang C, Wang J, Wang SS, Weiderpass E, Weinstein SJ, Wentzensen N, Wheeler W, White E, Wiencke JK, Wolk A, Wolpin BM, Wong MP, Wrensch M, Wu C, Wu T, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Yang HP, Yang PC, Yatabe Y, Ye Y, Yeboah ED, Yin Z, Ying C, Yu CJ, Yu K, Yuan JM, Zanetti KA, Zeleniuch-Jacquotte A, Zheng W, Zhou B, Mirabello L, Savage SA, Kraft P, Chanock SJ, Yeager M, Landi MT, Shi J, Chatterjee N, Amundadottir LT. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33. PMID: 25027329.
      View in: PubMed
    34. Boikos SA, Helman LJ, Stratakis CA. Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med. 2014 07 03; 371(1):85-6. PMID: 24988575.
      View in: PubMed
    35. Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. 2014 Aug 15; 20(16):4200-9. PMID: 24803583.
      View in: PubMed
    36. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014 Aug 15; 120(16):2448-56. PMID: 24797726.
      View in: PubMed
    37. Arnaldez FI, Helman LJ. New strategies in ewing sarcoma: lost in translation? Clin Cancer Res. 2014 Jun 15; 20(12):3050-6. PMID: 24756371.
      View in: PubMed
    38. Kang Z, Yu Y, Zhu YJ, Davis S, Walker R, Meltzer PS, Helman LJ, Cao L. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma. Oncogene. 2014 Dec 11; 33(50):5697-705. PMID: 24292683.
      View in: PubMed
    39. Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res. 2014 Mar 01; 20(5):1190-203. PMID: 24277455.
      View in: PubMed
    40. Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, Barkauskas DA, Marina N, de Toledo SR, Petrilli AS, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter DJ, Malats N, Kogevinas M, Wacholder S, Troisi R, Helman L, Fraumeni JF, Yeager M, Hoover RN, Chanock SJ. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013 Jul; 45(7):799-803. PMID: 23727862.
      View in: PubMed
    41. Kelly L, Bryan K, Kim SY, Janeway KA, Killian JK, Schildhaus HU, Miettinen M, Helman L, Meltzer PS, van de Rijn M, Debiec-Rychter M, O'Sullivan M. Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]. PLoS One. 2013; 8(5):e64102. PMID: 23717541.
      View in: PubMed
    42. Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013 Jun 20; 31(18):2296-302. PMID: 23630200.
      View in: PubMed
    43. Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, Quezado M, Smith WI, Jahromi MS, Xekouki P, Szarek E, Walker RL, Lasota J, Raffeld M, Klotzle B, Wang Z, Jones L, Zhu Y, Wang Y, Waterfall JJ, O'Sullivan MJ, Bibikova M, Pacak K, Stratakis C, Janeway KA, Schiffman JD, Fan JB, Helman L, Meltzer PS. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013 Jun; 3(6):648-57. PMID: 23550148.
      View in: PubMed
    44. Borges AA, Lemme EM, Abrahao LJ, Madureira D, Andrade MS, Soldan M, Helman L. Pneumatic dilation versus laparoscopic Heller myotomy for the treatment of achalasia: variables related to a good response. Dis Esophagus. 2014 Jan; 27(1):18-23. PMID: 23551592.
      View in: PubMed
    45. Miettinen M, Killian JK, Wang ZF, Lasota J, Lau C, Jones L, Walker R, Pineda M, Zhu YJ, Kim SY, Helman L, Meltzer P. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol. 2013 Feb; 37(2):234-40. PMID: 23282968.
      View in: PubMed
    46. Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene. 2013 Nov 21; 32(47):5429-38. PMID: 23318429.
      View in: PubMed
    47. Lasota J, Wang Z, Kim SY, Helman L, Miettinen M. Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol. 2013 Jan; 37(1):114-9. PMID: 22892600.
      View in: PubMed
    48. Grohar PJ, Helman LJ. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther. 2013 Feb; 137(2):216-24. PMID: 23085431.
      View in: PubMed
    49. Teicher BA, Linehan WM, Helman LJ. Targeting cancer metabolism. Clin Cancer Res. 2012 Oct 15; 18(20):5537-45. PMID: 23071355.
      View in: PubMed
    50. Wan X, Yeung C, Kim SY, Dolan JG, Ngo VN, Burkett S, Khan J, Staudt LM, Helman LJ. Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma. Cancer Res. 2012 Nov 15; 72(22):5889-99. PMID: 23002205.
      View in: PubMed
    51. Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R. The first European interdisciplinary ewing sarcoma research summit. Front Oncol. 2012; 2:54. PMID: 22662320.
      View in: PubMed
    52. Schayek H, Bentov I, Jacob-Hirsch J, Yeung C, Khanna C, Helman LJ, Plymate SR, Werner H. Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer. Horm Metab Res. 2012 Jun; 44(7):511-9. PMID: 22495974.
      View in: PubMed
    53. Wiener L, Battles H, Zadeh S, Smith CJ, Helman LJ, Kim SY. Gastrointestinal stromal tumor: psychosocial characteristics and considerations. Support Care Cancer. 2012 Jun; 20(6):1343-9. PMID: 22426502.
      View in: PubMed
    54. Arnaldez FI, Helman LJ. Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am. 2012 Jun; 26(3):527-42, vii-viii. PMID: 22520978.
      View in: PubMed
    55. Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, Reinke D, Chugh R, Benjamin RS, Helman LJ. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 2012; 17(3):321. PMID: 22363068.
      View in: PubMed
    56. Meltzer PS, Helman LJ. Genomic investigation of dedifferentiated liposarcoma suggests a role for therapeutic targeting of the tumor epigenome. Cancer Discov. 2011 Dec; 1(7):555-6. PMID: 22586679.
      View in: PubMed
    57. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011 Dec 01; 29(34):4541-7. PMID: 22025149.
      View in: PubMed
    58. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst. 2011 Jun 22; 103(12):962-78. PMID: 21653923.
      View in: PubMed
    59. Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia. 2011 Feb; 13(2):145-53. PMID: 21403840.
      View in: PubMed
    60. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011 Mar 01; 29(7):917-24. PMID: 21282551.
      View in: PubMed
    61. Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, Lai AH, Kelly L, Hornick JL, O'Sullivan M, de Krijger RR, Dinjens WN, Demetri GD, Antonescu CR, Fletcher JA, Helman L, Stratakis CA. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011 Jan 04; 108(1):314-8. PMID: 21173220.
      View in: PubMed
    62. Mayeenuddin LH, Yu Y, Kang Z, Helman LJ, Cao L. Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L). Oncogene. 2010 Dec 02; 29(48):6367-77. PMID: 20818434.
      View in: PubMed
    63. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, Yang F, Pineda M, Helman LJ, Meltzer PS. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010 Aug 15; 70(16):6497-508. PMID: 20663909.
      View in: PubMed
    64. Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM, Balis FM. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res. 2009 Dec 01; 15(23):7361-7. PMID: 19920107.
      View in: PubMed
    65. Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ, Khan J. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009 Nov; 119(11):3395-407. PMID: 19809159.
      View in: PubMed
    66. Fitzhugh CD, Wise B, Baird K, Tsokos M, Helman L, Mackall C, Savage SA, Warren KE. Secondary supratentorial primitive neuroectodermal tumor following treatment of childhood osteosarcoma. Pediatr Blood Cancer. 2009 Sep; 53(3):496-8. PMID: 19434734.
      View in: PubMed
    67. Wan X, Kim SY, Guenther LM, Mendoza A, Briggs J, Yeung C, Currier D, Zhang H, Mackall C, Li WJ, Tuan RS, Deyrup AT, Khanna C, Helman L. Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene. 2009 Sep 24; 28(38):3401-11. PMID: 19597468.
      View in: PubMed
    68. Kim SY, Wan X, Helman LJ. Targeting IGF-1R in the treatment of sarcomas: past, present and future. Bull Cancer. 2009 Jul-Aug; 96(7):E52-60. PMID: 19617179.
      View in: PubMed
    69. Hong SH, Briggs J, Newman R, Hoffman K, Mendoza A, LeRoith D, Helman L, Yakar S, Khanna C. Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. Int J Cancer. 2009 May 01; 124(9):2042-9. PMID: 19132750.
      View in: PubMed
    70. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009 Jun 01; 27(16):2705-11. PMID: 19364967.
      View in: PubMed
    71. Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. Oncologist. 2009 Jan; 14(1):83-91. PMID: 19126579.
      View in: PubMed
    72. Kim SY, Helman LJ. Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res. 2009; 152:517-28. PMID: 20213413.
      View in: PubMed
    73. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, Lee FY, Gottardis MM, Clark E, Helman L, Attar RM, Dongre A, Carboni JM. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 2009 Jan 01; 69(1):161-70. PMID: 19117999.
      View in: PubMed
    74. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, Khanna C, Helman LJ. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008 Oct 01; 68(19):8039-48. PMID: 18829562.
      View in: PubMed
    75. Wayne AS, Reaman GH, Helman LJ. Progress in the curative treatment of childhood hematologic malignancies. J Natl Cancer Inst. 2008 Sep 17; 100(18):1271-3. PMID: 18780861.
      View in: PubMed
    76. Mussai FJ, Cunningham LC, Rezvani G, Stratakis CA, Reynolds JC, Nesterova G, Henshaw RM, Levine JE, Helman LJ, Arthur DC, Kim SY. Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion syndrome. J Pediatr Hematol Oncol. 2008 Aug; 30(8):612-7. PMID: 18799940.
      View in: PubMed
    77. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008 Aug 01; 14(15):4850-8. PMID: 18676758.
      View in: PubMed
    78. Bielack SS, Marina N, Ferrari S, Helman LJ, Smeland S, Whelan JS, Reaman GH. Osteosarcoma: the same old drugs or more? J Clin Oncol. 2008 Jun 20; 26(18):3102-3; author reply 3104-5. PMID: 18565904.
      View in: PubMed
    79. Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Designing phase 0 cancer clinical trials. Clin Cancer Res. 2008 Jun 15; 14(12):3675-82. PMID: 18559582.
      View in: PubMed
    80. Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH. Phase 0 clinical trials: conceptions and misconceptions. Cancer J. 2008 May-Jun; 14(3):133-7. PMID: 18536551.
      View in: PubMed
    81. Kim SY, Tsokos M, Helman LJ. Dilemmas associated with congenital ewing sarcoma family tumors. J Pediatr Hematol Oncol. 2008 Jan; 30(1):4-7. PMID: 18176172.
      View in: PubMed
    82. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, Salari H, Zhang H, Hwang ST, Khanna C, Helman LJ. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008; 25(3):201-11. PMID: 18071913.
      View in: PubMed
    83. Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv. 2007 Dec; 7(6):325-34. PMID: 18199854.
      View in: PubMed
    84. Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, Chen B, Veenstra T, Hewitt SM, Helman LJ, Khanna C, Weissman AM. The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat Med. 2007 Dec; 13(12):1504-9. PMID: 18037895.
      View in: PubMed
    85. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007 Aug; 12(8):1007-18. PMID: 17766661.
      View in: PubMed
    86. Paz-Priel I, Long L, Helman LJ, Mackall CL, Wayne AS. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol. 2007 Apr 20; 25(12):1519-24. PMID: 17442994.
      View in: PubMed
    87. Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ, Qualman S, Tsokos M, Krishnan K, Helman LJ, Liotta LA. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007 Apr 01; 67(7):3431-40. PMID: 17409454.
      View in: PubMed
    88. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer. 2007 02; 7(2):131-9. PMID: 17251919.
      View in: PubMed
    89. Merchant MS, Melchionda F, Sinha M, Khanna C, Helman L, Mackall CL. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol Immunother. 2007 Jul; 56(7):1037-46. PMID: 17149595.
      View in: PubMed
    90. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007 Mar 22; 26(13):1932-40. PMID: 17001314.
      View in: PubMed
    91. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis. 2006; 23(3-4):227-36. PMID: 17028919.
      View in: PubMed
    92. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia. 2006 May; 8(5):394-401. PMID: 16790088; PMCID: PMC1592447.
    93. Krishnan K, Khanna C, Helman LJ. The molecular biology of pulmonary metastasis. Thorac Surg Clin. 2006 May; 16(2):115-24. PMID: 16805200.
      View in: PubMed
    94. Terabe M, Khanna C, Bose S, Melchionda F, Mendoza A, Mackall CL, Helman LJ, Berzofsky JA. CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. Cancer Res. 2006 Apr 01; 66(7):3869-75. PMID: 16585215.
      View in: PubMed
    95. van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res. 2006 Feb 01; 66(3):1818-23. PMID: 16452243.
      View in: PubMed
    96. Khanna C, Helman LJ. Molecular approaches in pediatric oncology. Annu Rev Med. 2006; 57:83-97. PMID: 16409138.
      View in: PubMed
    97. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ, Mackall CL. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 2005 Nov; 11(11):1238-43. PMID: 16227988.
      View in: PubMed
    98. Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong KK, Lau CC. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005 Sep 15; 65(18):8142-50. PMID: 16166288.
      View in: PubMed
    99. Capponcelli S, Pedrini E, Cerone MA, Corti V, Fontanesi S, Alessio M, Bachi A, Soddu S, Ribatti D, Picci P, Helman LJ, Cantelli-Forti G, Sangiorgi L. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation. Hum Mutat. 2005 Aug; 26(2):94-103. PMID: 15977174.
      View in: PubMed
    100. Krishnan K, Khanna C, Helman LJ. The biology of metastases in pediatric sarcomas. Cancer J. 2005 Jul-Aug; 11(4):306-13. PMID: 16197720.
      View in: PubMed
    101. Savage SA, Stewart BJ, Liao JS, Helman LJ, Chanock SJ. Telomere stability genes are not mutated in osteosarcoma cell lines. Cancer Genet Cytogenet. 2005 Jul 01; 160(1):79-81. PMID: 15949576.
      View in: PubMed
    102. Nathan PC, Tsokos M, Long L, Bernstein D, Wexler LH, Mackall CL, Helman LJ. Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience. Pediatr Blood Cancer. 2005 May; 44(5):449-54. PMID: 15547929.
      View in: PubMed
    103. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005 Mar 15; 65(6):2406-11. PMID: 15781656.
      View in: PubMed
    104. LeRoith D, Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell. 2004 Mar; 5(3):201-2. PMID: 15050909.
      View in: PubMed
    105. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004 Feb; 10(2):182-6. PMID: 14704791.
      View in: PubMed
    106. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004 Feb; 10(2):175-81. PMID: 14704789.
      View in: PubMed
    107. Navid F, Mischen BT, Helman LJ. Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines. Sarcoma. 2004; 8(1):25-30. PMID: 18521390.
      View in: PubMed
    108. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003 Nov 15; 9(15):5442-53. PMID: 14654523.
      View in: PubMed
    109. Wan X, Helman LJ. Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells. Oncogene. 2003 Nov 06; 22(50):8205-11. PMID: 14603261.
      View in: PubMed
    110. Zhang H, Merchant MS, Chua KS, Khanna C, Helman LJ, Telford B, Ward Y, Summers J, Toretsky J, Thomas EK, June CH, Mackall CL. Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol Ther. 2003 Sep-Oct; 2(5):579-86. PMID: 14614331.
      View in: PubMed
    111. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003 Sep; 3(9):685-94. PMID: 12951587.
      View in: PubMed
    112. Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest. 2003 Sep; 83(9):1255-65. PMID: 13679433.
      View in: PubMed
    113. Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003 Apr 15; 21(8):1574-80. PMID: 12697883.
      View in: PubMed
    114. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002 Dec; 8(12):3646-57. PMID: 12473573.
      View in: PubMed
    115. Sharp R, Recio JA, Jhappan C, Otsuka T, Liu S, Yu Y, Liu W, Anver M, Navid F, Helman LJ, DePinho RA, Merlino G. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med. 2002 Nov; 8(11):1276-80. PMID: 12368906.
      View in: PubMed
    116. Wan X, Helman LJ. Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia. 2002 Sep-Oct; 4(5):400-8. PMID: 12192598; PMCID: PMC1564119.
    117. Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell. 2002 Sep; 2(3):175-8. PMID: 12242149.
      View in: PubMed
    118. Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, Bernstein D, Mackall CL, Hawkins DS, Helman LJ. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol. 2002 Aug-Sep; 24(6):440-6. PMID: 12218590.
      View in: PubMed
    119. Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, Bose SM, Hong SH, Hewitt SM, Helman LJ. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res. 2002 Jul; 8(7):2406-12. PMID: 12114446.
      View in: PubMed
    120. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol. 2002 Mar; 38(3):158-64. PMID: 11836714.
      View in: PubMed
    121. Gobbi G, Sangiorgi L, Lenzi L, Casadei R, Canaider S, Strippoli P, Lucarelli E, Ghedini I, Donati D, Fabbri N, Warzecha J, Yeoung C, Helman LJ, Picci P, Carinci P. Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol. 2002 Jan; 20(1):143-7. PMID: 11743655.
      View in: PubMed
    122. Toretsky JA, Steinberg SM, Thakar M, Counts D, Pironis B, Parente C, Eskenazi A, Helman L, Wexler LH. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer. 2001 Dec 01; 92(11):2941-7. PMID: 11753970.
      View in: PubMed
    123. Dupont J, Khan J, Qu BH, Metzler P, Helman L, LeRoith D. Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology. 2001 Nov; 142(11):4969-75. PMID: 11606465.
      View in: PubMed
    124. Weil RJ, Zhuang Z, Pack S, Kumar S, Helman L, Fuller BG, Mackall CL, Oldfield EH. Intramedullary Ewing sarcoma of the spinal cord: consequences of molecular diagnostics. Case report. J Neurosurg. 2001 Oct; 95(2 Suppl):270-5. PMID: 11599852.
      View in: PubMed
    125. Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001 Sep 15; 61(18):6868-75. PMID: 11559563.
      View in: PubMed
    126. Merino ME, Navid F, Christensen BL, Toretsky JA, Helman LJ, Cheung NK, Mackall CL. Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction. J Clin Oncol. 2001 Aug 15; 19(16):3649-59. PMID: 11504746.
      View in: PubMed
    127. Benjamin R, Helman L, Meyers P, Reaman G. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum Gene Ther. 2001 Aug 10; 12(12):1591-3. PMID: 11529247.
      View in: PubMed
    128. Mackall CL, Helman LJ. High-dose chemotherapy for rhabdomyosarcoma: where do we go from here. J Pediatr Hematol Oncol. 2001 Jun-Jul; 23(5):266-7. PMID: 11464979.
      View in: PubMed
    129. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001 May 01; 61(9):3750-9. PMID: 11325848.
      View in: PubMed
    130. Dagher R, Pham TA, Sorbara L, Kumar S, Long L, Bernstein D, Mackall C, Raffeld M, Tsokos M, Helman L. Molecular confirmation of Ewing sarcoma. J Pediatr Hematol Oncol. 2001 May; 23(4):221-4. PMID: 11846300.
      View in: PubMed
    131. Dupont J, Fernandez AM, Glackin CA, Helman L, LeRoith D. Insulin-like growth factor 1 (IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor. J Biol Chem. 2001 Jul 13; 276(28):26699-707. PMID: 11323435.
      View in: PubMed
    132. Mackall CL, Helman LJ. Targeting pediatric malignancies for T cell-mediated immune responses. Curr Oncol Rep. 2000 Nov; 2(6):539-46. PMID: 11122890.
      View in: PubMed
    133. Liu XF, Helman LJ, Yeung C, Bera TK, Lee B, Pastan I. XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. Cancer Res. 2000 Sep 01; 60(17):4752-5. PMID: 10987281.
      View in: PubMed
    134. Mackall C, Berzofsky J, Helman LJ. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin Orthop Relat Res. 2000 Apr; (373):25-31. PMID: 10810459.
      View in: PubMed
    135. Cope JU, Tsokos M, Helman LJ, Gridley G, Tucker MA. Inguinal hernia in patients with Ewing sarcoma: a clue to etiology. Med Pediatr Oncol. 2000 Mar; 34(3):195-9. PMID: 10696126.
      View in: PubMed
    136. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 2000; 18(3):261-71. PMID: 11315100.
      View in: PubMed
    137. Navid F, Letterio JJ, Yeung CL, Pegtel M, Helman LJ. Autocrine Transforming Growth Factor-beta Growth Pathway in Murine Osteosarcoma Cell Lines Associated with Inability to Affect Phosphorylation of Retinoblastoma Protein. Sarcoma. 2000; 4(3):93-102. PMID: 18521287.
      View in: PubMed
    138. Merlino G, Helman LJ. Rhabdomyosarcoma--working out the pathways. Oncogene. 1999 Sep 20; 18(38):5340-8. PMID: 10498887.
      View in: PubMed
    139. Zhang L, Kim M, Choi YH, Goemans B, Yeung C, Hu Z, Zhan S, Seth P, Helman LJ. Diminished G1 checkpoint after gamma-irradiation and altered cell cycle regulation by insulin-like growth factor II overexpression. J Biol Chem. 1999 May 07; 274(19):13118-26. PMID: 10224065.
      View in: PubMed
    140. Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist. 1999; 4(1):34-44. PMID: 10337369.
      View in: PubMed
    141. Wang W, Kumar P, Wang W, Epstein J, Helman L, Moore JV, Kumar S. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res. 1998 Oct 01; 58(19):4426-33. PMID: 9766674.
      View in: PubMed
    142. Zhang L, Zhan S, Navid F, Li Q, Choi YH, Kim M, Seth P, Helman LJ. AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma. Oncogene. 1998 Sep 10; 17(10):1261-70. PMID: 9771969.
      View in: PubMed
    143. Zhan S, Zhang L, Van M, Young C, Helman LJ. Biallelic expression of all four IGF-II promoters and its association with increased methylation of H19 gene in human brain. Brain Res. 1998 May 11; 792(2):283-90. PMID: 9593943.
      View in: PubMed
    144. Zhan S, Helman LJ. Glimpsing the cause of rhabdomyosarcoma. Nat Med. 1998 May; 4(5):559-60. PMID: 9585226.
      View in: PubMed
    145. Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, Helman LJ. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer. 1998 Apr 13; 76(2):223-7. PMID: 9537584.
      View in: PubMed
    146. Zhang L, Zhan Q, Zhan S, Kashanchi F, Fornace AJ, Seth P, Helman LJ. p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. DNA Cell Biol. 1998 Feb; 17(2):125-31. PMID: 9502429.
      View in: PubMed
    147. Goletz TJ, Mackall CL, Berzofsky JA, Helman LJ. Molecular alterations in pediatric sarcomas: potential targets for immunotherapy. Sarcoma. 1998; 2(2):77-87. PMID: 18521238.
      View in: PubMed
    148. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997 Dec 05; 272(49):30822-7. PMID: 9388225.
      View in: PubMed
    149. Toretsky JA, Helman LJ. Cytogenetics and experimental models. Curr Opin Oncol. 1997 Jul; 9(4):342-7. PMID: 9251884.
      View in: PubMed
    150. Schulte TW, Toretsky JA, Ress E, Helman L, Neckers LM. Expression of PAX3 in Ewing's sarcoma family of tumors. Biochem Mol Med. 1997 Apr; 60(2):121-6. PMID: 9169092.
      View in: PubMed
    151. Blakesley VA, Stannard BS, Kalebic T, Helman LJ, LeRoith D. Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol. 1997 Mar; 152(3):339-44. PMID: 9071953.
      View in: PubMed
    152. Weintraub M, Kalebic T, Helman LJ, Bhatia KG. Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma. Sarcoma. 1997; 1(3-4):135-41. PMID: 18521215.
      View in: PubMed
    153. Kalebic T, Tsokos M, Helman LJ. Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470. Int J Cancer. 1996 Nov 27; 68(5):596-9. PMID: 8938140.
      View in: PubMed
    154. Toretsky JA, Helman LJ. Involvement of IGF-II in human cancer. J Endocrinol. 1996 Jun; 149(3):367-72. PMID: 8691094.
      View in: PubMed
    155. Zhang L, Kashanchi F, Zhan Q, Zhan S, Brady JN, Fornace AJ, Seth P, Helman LJ. Regulation of insulin-like growth factor II P3 promotor by p53: a potential mechanism for tumorigenesis. Cancer Res. 1996 Mar 15; 56(6):1367-73. PMID: 8640827.
      View in: PubMed
    156. Blakesley VA, Kalebic T, Helman LJ, Stannard B, Faria TN, Roberts CT, LeRoith D. Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor. Endocrinology. 1996 Feb; 137(2):410-7. PMID: 8593783.
      View in: PubMed
    157. Kalebic T, Judde JG, Velez-Yanguas M, Knutsen T, Helman LJ. Metastatic human rhabdomyosarcoma: molecular, cellular and cytogenetic analysis of a novel cellular model. Invasion Metastasis. 1996; 16(2):83-96. PMID: 9030243.
      View in: PubMed
    158. Velez-Yanguas MC, Kalebic T, Maggi M, Kappel CC, Letterio J, Uskokovic M, Helman LJ. 1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. J Clin Endocrinol Metab. 1996 Jan; 81(1):93-9. PMID: 8550801.
      View in: PubMed
    159. Zhan S, Shapiro DN, Helman LJ. Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene. 1995 Dec 21; 11(12):2503-7. PMID: 8545106.
      View in: PubMed
    160. Hernández-Sánchez C, Blakesley V, Kalebic T, Helman L, LeRoith D. The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. J Biol Chem. 1995 Dec 08; 270(49):29176-81. PMID: 7493944.
      View in: PubMed
    161. Zhan S, Shapiro D, Zhan S, Zhang L, Hirschfeld S, Elassal J, Helman LJ. Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer. J Biol Chem. 1995 Nov 24; 270(47):27983-6. PMID: 7499276.
      View in: PubMed
    162. LeRoith D, Werner H, Neuenschwander S, Kalebic T, Helman LJ. The role of the insulin-like growth factor-I receptor in cancer. Ann N Y Acad Sci. 1995 Sep 07; 766:402-8. PMID: 7486685.
      View in: PubMed
    163. Lee YL, Helman L, Hoffman T, Laborda J. dlk, pG2 and Pref-1 mRNAs encode similar proteins belonging to the EGF-like superfamily. Identification of polymorphic variants of this RNA. Biochim Biophys Acta. 1995 Apr 04; 1261(2):223-32. PMID: 7711066.
      View in: PubMed
    164. Minniti CP, Luan D, O'Grady C, Rosenfeld RG, Oh Y, Helman LJ. Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ. 1995 Mar; 6(3):263-9. PMID: 7794794.
      View in: PubMed
    165. Gaetano C, Manni I, Bossi G, Piaggio G, Soddu S, Farina A, Helman LJ, Sacchi A. Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells. Eur J Cancer. 1995; 31A(4):447-52. PMID: 7576943.
      View in: PubMed
    166. LeRoith D, Baserga R, Helman L, Roberts CT. Insulin-like growth factors and cancer. Ann Intern Med. 1995 Jan 01; 122(1):54-9. PMID: 7619109.
      View in: PubMed
    167. Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. 1994 Nov 01; 54(21):5531-4. PMID: 7923191.
      View in: PubMed
    168. Wexler LH, Helman LJ. Pediatric soft tissue sarcomas. CA Cancer J Clin. 1994 Jul-Aug; 44(4):211-47. PMID: 8019928.
      View in: PubMed
    169. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest. 1994 Jul; 94(1):445-8. PMID: 8040287.
      View in: PubMed
    170. Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res. 1994 May 15; 54(10):2803-7. PMID: 8168113.
      View in: PubMed
    171. Luján HD, Mowatt MR, Helman LJ, Nash TE. Insulin-like growth factors stimulate growth and L-cysteine uptake by the intestinal parasite Giardia lamblia. J Biol Chem. 1994 May 06; 269(18):13069-72. PMID: 8175729.
      View in: PubMed
    172. Minniti CP, Tsokos M, Newton WA, Helman LJ. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am J Clin Pathol. 1994 Feb; 101(2):198-203. PMID: 8116575.
      View in: PubMed
    173. Hirschfeld S, Helman L. Diverse roles of insulin-like growth factors in pediatric solid tumors. In Vivo. 1994 Jan-Feb; 8(1):81-90. PMID: 8054516.
      View in: PubMed
    174. Parmer RJ, Xi XP, Wu HJ, Helman LJ, Petz LN. Secretory protein traffic. Chromogranin A contains a dominant targeting signal for the regulated pathway. J Clin Invest. 1993 Aug; 92(2):1042-54. PMID: 8394383.
      View in: PubMed
    175. Crouch GD, Kalebic T, Tsokos M, Helman LJ. Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line. Exp Cell Res. 1993 Feb; 204(2):210-6. PMID: 8440318.
      View in: PubMed
    176. Minniti CP, Helman LJ. IGF-II in the pathogenesis of rhabdomyosarcoma: a prototype of IGFs involvement in human tumorigenesis. Adv Exp Med Biol. 1993; 343:327-43. PMID: 7514344.
      View in: PubMed
    177. Park JG, Choe GY, Helman LJ, Gazdar AF, Yang HK, Kim JP, Park SH, Kim YI. Chromogranin-A expression in gastric and colon cancer tissues. Int J Cancer. 1992 May 08; 51(2):189-94. PMID: 1349007.
      View in: PubMed
    178. Minniti CP, Kohn EC, Grubb JH, Sly WS, Oh Y, Müller HL, Rosenfeld RG, Helman LJ. The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells. J Biol Chem. 1992 May 05; 267(13):9000-4. PMID: 1315746.
      View in: PubMed
    179. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ, Helman LJ. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992 Apr 15; 52(8):2243-7. PMID: 1559227.
      View in: PubMed
    180. Minniti CP, Maggi M, Helman LJ. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res. 1992 Apr 01; 52(7):1830-5. PMID: 1312901.
      View in: PubMed
    181. Crouch GD, Helman LJ. All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines. Cancer Res. 1991 Sep 15; 51(18):4882-7. PMID: 1893378.
      View in: PubMed
    182. Helman LJ, Thiele CJ. New insights into the causes of cancer. Pediatr Clin North Am. 1991 Apr; 38(2):201-21. PMID: 2006074.
      View in: PubMed
    183. El-Badry OM, Helman LJ, Chatten J, Steinberg SM, Evans AE, Israel MA. Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest. 1991 Feb; 87(2):648-57. PMID: 1991849.
      View in: PubMed
    184. Cooper MJ, Hutchins GM, Cohen PS, Helman LJ, Israel MA. Neuroblastoma cell lines mimic chromaffin neuroblast maturation. Prog Clin Biol Res. 1991; 366:343-50. PMID: 1676846.
      View in: PubMed
    185. Prior TI, Helman LJ, FitzGerald DJ, Pastan I. Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin. Cancer Res. 1991 Jan 01; 51(1):174-80. PMID: 1846308.
      View in: PubMed
    186. Cohen PS, Cooper MJ, Helman LJ, Thiele CJ, Seeger RC, Israel MA. Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res. 1990 Sep 15; 50(18):6055-61. PMID: 2393870.
      View in: PubMed
    187. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ. 1990 Jul; 1(7):325-31. PMID: 2177632.
      View in: PubMed
    188. Levine MA, Dempsey MA, Helman LJ, Ahn TG. Expression of chromogranin-A messenger ribonucleic acid in parathyroid tissue from patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 1990 Jun; 70(6):1668-73. PMID: 2347900.
      View in: PubMed
    189. Cooper MJ, Hutchins GM, Cohen PS, Helman LJ, Mennie RJ, Israel MA. Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts. Cell Growth Differ. 1990 Apr; 1(4):149-59. PMID: 1982060.
      View in: PubMed
    190. Levine MA, Smallwood PM, Moen PT, Helman LJ, Ahn TG. Molecular cloning of beta 3 subunit, a third form of the G protein beta-subunit polypeptide. Proc Natl Acad Sci U S A. 1990 Mar; 87(6):2329-33. PMID: 2107550.
      View in: PubMed
    191. Helman LJ, Sack N, Plon SE, Israel MA. The sequence of an adrenal specific human cDNA, pG2. Nucleic Acids Res. 1990 Feb 11; 18(3):685. PMID: 2308864.
      View in: PubMed
    192. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol. 1989 Nov; 7(11):1720-5. PMID: 2809684.
      View in: PubMed
    193. El-Badry OM, Romanus JA, Helman LJ, Cooper MJ, Rechler MM, Israel MA. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest. 1989 Sep; 84(3):829-39. PMID: 2547840.
      View in: PubMed
    194. Reeves SA, Helman LJ, Allison A, Israel MA. Molecular cloning and primary structure of human glial fibrillary acidic protein. Proc Natl Acad Sci U S A. 1989 Jul; 86(13):5178-82. PMID: 2740350.
      View in: PubMed
    195. Peng ZG, Calvert I, Clark J, Helman L, Kahn R, Kung HF. Molecular cloning, sequence analysis and mRNA expression of human ADP-ribosylation factor. Biofactors. 1989 Mar; 2(1):45-9. PMID: 2535313.
      View in: PubMed
    196. Helman LJ, Ahn TG, Levine MA, Allison A, Cohen PS, Cooper MJ, Cohn DV, Israel MA. Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA. J Biol Chem. 1988 Aug 15; 263(23):11559-63. PMID: 3403545.
      View in: PubMed
    197. Helman LJ, Gazdar AF, Park JG, Cohen PS, Cotelingam JD, Israel MA. Chromogranin A expression in normal and malignant human tissues. J Clin Invest. 1988 Aug; 82(2):686-90. PMID: 3403722.
      View in: PubMed
    198. Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM, Park JG. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 1988 Jul 15; 48(14):4078-82. PMID: 3383200.
      View in: PubMed
    199. Cooper MJ, Helman LJ, Evans AE, Swamy S, O'Connor DT, Helson L, Israel MA. Chromogranin A expression in childhood peripheral neuroectodermal tumors. Prog Clin Biol Res. 1988; 271:175-84. PMID: 2841667.
      View in: PubMed
    200. Helman LJ, Thiele CJ, Linehan WM, Nelkin BD, Baylin SB, Israel MA. Molecular markers of neuroendocrine development and evidence of environmental regulation. Proc Natl Acad Sci U S A. 1987 Apr; 84(8):2336-9. PMID: 3470797.
      View in: PubMed
    201. Israel MA, Helman LJ, Miser J. Patterns of proto-oncogene expression: a novel approach to the development of tumor markers. Important Adv Oncol. 1987; 87-104. PMID: 2841235.
      View in: PubMed
    202. Plaut SM, Walker-Bartnick L, Helman L, Ginsberg R, Rapoport RG, Plaut JM, Cannon MT, Dies RR. Improving staff-student relations: effects of a humanistic medicine programme. Med Teach. 1980; 2(1):32-9. PMID: 24480004.
      View in: PubMed
    203. Von Hoff DD, Penta JS, Helman LJ, Slavik M. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep. 1977 Jul; 61(4):745-8. PMID: 301783.
      View in: PubMed